English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduResearchers at Children’s Hospital of Philadelphia (CHOP) revealed for the first time that children, adolescents and young adults may experience very rare neurological issues of paraparesis and quadriparesis following chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy used to treat B-cell Acute Lymphoblastic Leukemia (B-ALL).
Tag: T-Cell
People with Long COVID Have Distinct Hormonal and Immune Differences From Those Without This Condition
Research conducted at Mount Sinai and Yale confirms long COVID is a biological disease by showing blood biomarkers that can predict who has it
CAR-T immune therapy attacks ovarian cancer in mice with a single dose
CAR-T immune therapies could be effective against solid tumors if the right targets are identified, a new study led by University of Illinois Urbana-Champaign researchers suggests. The researchers successfully deployed CAR-T in a mouse model of ovarian cancer, a type of aggressive, solid-tumor cancer that has eluded such therapies until now.
Scientists prevent “exhaustion” in cancer-fighting T cells
The new study paves the way toward more effective cancer immunotherapies.
Simmons Cancer Center, MD Anderson Scientists Develop Artificial Intelligence Method To Predict Anti-Cancer Immunity
Researchers and data scientists at UT Southwestern Medical Center and MD Anderson Cancer Center have developed an artificial intelligence technique that can identify which cell surface peptides produced by cancer cells called neoantigens are recognized by the immune system.
World-first COVID vaccine booster randomized clinical trial in transplant patients proves third shot is very effective
The study enrolled 120 transplant patients between May 25th and June 3rd. None of them had COVID previously and all of them had received two doses of the Moderna vaccine. Half of the participants received a third shot of the vaccine (at the 2-month mark after their second dose) and the other half received placebo.
The primary outcome was based on antibody level greater than 100 U/ml against the spike protein of the virus. In the placebo group – after three doses (where the third dose was placebo), the response rate was only 18% whereas in the Moderna three-dose group, the response rate was 55%.
Recruiting Starts at University of Miami Health System for NIH Study of COVID-19 Immunity
The University of Miami Health System is one of five sites nationally and the only one in the Southeast U.S. chosen to participate in a National Institute of Allergy and Infectious Diseases (NIAID) study looking at people who have had COVID-19 or have had a COVID-19 vaccine to examine the durability and robustness of participants’ antibody and T-cell responses to the virus.
Roswell Park Reports Positive Outcomes from New Combination Treatment for Ovarian Cancer
A team from Roswell Park Comprehensive Cancer Center has detailed striking findings on the effectiveness of a previously untried combination of old and new drugs as treatment for recurrent ovarian cancer.